Picture loading failed.

Anti-ITGA4 therapeutic antibody (Pre-made Natalizumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Natalizumab, sold under the brand name Tysabri among others, is a medication used to treat multiple sclerosis and Crohn's disease. It is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin. It is given by intravenous infusion every 28 days. The drug is believed to work by reducing the ability of inflammatory immune cells to attach to and pass through the cell layers lining the intestines and blood–brain barrier. Natalizumab has proven effective in treating the symptoms of both diseases, preventing relapse, vision loss, cognitive decline and significantly improving quality of life in people with multiple sclerosis, as well as increasing rates of remission and preventing relapse in multiple sclerosis.

Order informatioin

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-367-1mg 1mg 3090
GMP-Bios-ab-367-10mg 10mg 21890
GMP-Bios-ab-367-100mg 100mg 148000
GMP-Bios-ab-367-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-ITGA4 therapeutic antibody (Pre-made Natalizumab biosimilar,Whole mAb)
INN Name Natalizumab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI StructureNone
99% SI Structure4irz:HL
95-98% SI StructureNone
Year Proposed1998
Year Recommended1999
CompaniesBiogen;Biogen Idec;Elan Corporation;Perrigo
Conditions ApprovedCrohn's disease;Multiple sclerosis
Conditions ActiveEpilepsy;Graft-versus-host disease;Stroke
Conditions DiscontinuedMultiple myeloma;Rheumatoid arthritis
Development Techna